UnknownPHASE1, PHASE2NCT00887042

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Korean Society of Pediatric Hematology Oncology
Principal Investigator
Hyo Seop Ahn, M.D, Ph. D
The Korean Society of Pediatric Hematology Oncology
Intervention
Fludarabine, Busulfan, Thymoglobulin(drug)
Enrollment
35 target
Eligibility
1-21 years · All sexes
Timeline
20062012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00887042 on ClinicalTrials.gov

Other trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Additional recruiting or active studies for the same condition.

See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

← Back to all trials